NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Autobahn Therapeutics

Autobahn Therapeutics

Private
San Diego, CaliforniaHealthcare & Life Scienceshttps://autobahntx.com/

Last Round

Series C

Jul 24, 2024

Total Funding Raised

$208.7M

Company Overview

Autobahn Therapeutics is a biotechnology company developing regenerative medicines and brain-targeting chemistry aimed at treating central nervous system disorders.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Mental Health, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biotechnologyCNS disorderssmall-molecule therapyneuroplasticitydrug discoveryclinical-stage biotechdepression treatmentcentral nervous systemFDA fast trackbiopharmarestorative medicineclinical trialspreclinical researchdrug pipelineneuroscience startup

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Autobahn Therapeutics Comps

Public and private peers based on sector, stage, and business model.

Autobahn Therapeutics comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Autobahn Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series CJul 24, 2024
Series B ExtensionSep 8, 2022
Series BJun 9, 2020

Key People

Founding team and executive leadership

Kevin Finney

Chairman And CEO

Executive Team

Autobahn Therapeutics Investors

Notable investors and investment history

Autobahn Therapeutics investors
InvestorRounds
Newpath PartnersSeries C
S32Series B Extension, Series C, Series B
ARCH Venture PartnersSeries C
TD SecuritiesSeries B Extension, Series B
Blue Owl CapitalSeries B Extension, Series C, Series B
Monograph CapitalSeries C
Invus OpportunitiesSeries B Extension

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 8, 2025

    Will present at Evercore's Emerging Private Biotech Conference.

  • Jul 24, 2024

    $100M round completed.

Autobahn Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Autobahn Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Autobahn Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersSan Diego, California
Employee Range35
Year Founded2017
Last FundingJul 24, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.